SELECT * FROM `stock_list` where symbol='A1LN34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` where symbol='A1LN34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "A1LN34" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Alnylam Pharmaceuticals (BSP:A1LN34) Purchase Of Property,
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Purchase Of Property, Plant, Equipment

Alnylam Pharmaceuticals (BSP:A1LN34) Purchase Of Property, Plant, Equipment : R$-309 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Purchase Of Property, Plant, Equipment?

Alnylam Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Dec. 2023 was R$-75 Mil. It means Alnylam Pharmaceuticals spent R$75 Mil on purchasing property, plant, equipment. Alnylam Pharmaceuticals's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2023 was R$-309Mil.

Compared with last quarter (R$-84 Mil in Sep. 2023 ), Alnylam Pharmaceuticals spent less money on purchasing property, plant, equipment in Dec. 2023 (R$-75 Mil).


Alnylam Pharmaceuticals Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Alnylam Pharmaceuticals's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Purchase Of Property, Plant, Equipment Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -575.27 -361.99 -431.88 -377.98 -304.82

Alnylam Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -113.48 -72.35 -77.27 -84.41 -75.01

Alnylam Pharmaceuticals Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-309 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry
Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines